Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Accounts Payables (2022 - 2025)

Pediatrix Medical (MD) has disclosed Accounts Payables for 11 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 19.84% to $37.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.2 million, a 19.84% decrease, with the full-year FY2025 number at $37.2 million, down 19.84% from a year prior.
  • Accounts Payables was $37.2 million for Q4 2025 at Pediatrix Medical, down from $38.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $374.2 million in Q4 2022 to a low of $37.2 million in Q4 2025.
  • A 4-year average of $189.3 million and a median of $234.2 million in 2025 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: fell 6.26% in 2023, then tumbled 86.76% in 2024.
  • Pediatrix Medical's Accounts Payables stood at $374.2 million in 2022, then dropped by 6.26% to $350.8 million in 2023, then crashed by 86.76% to $46.4 million in 2024, then decreased by 19.84% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Accounts Payables are $37.2 million (Q4 2025), $38.7 million (Q3 2025), and $42.1 million (Q2 2025).